Clinical Trial Search

Phase 3 N=2,274 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) — -1.5; -1.2 Percentage of HbA1c — p=<0.0001

Novo Nordisk A/S Results May 2022 8.6% serious AE View details

Phase 3 N=33 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 96.4; 97.0 percentage of participants

AbbVie Results May 2022 9.1% serious AE View details

Phase 3 N=947 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

Primary: Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20 — 17.58; 14.59 Months — p=0.0469

Bristol-Myers Squibb Results May 2022 66.3% serious AE View details

Phase 3 N=228 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Atopic Dermatitis

Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2-points From Baseline to Week 16. — 22.1; 41.2 percentage of…

Eli Lilly and Company Results May 2022 1.3% serious AE View details

Phase 3 N=42 Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Cluster Headache

Primary: Percentage of Subjects Who Achieve Pain Relief — 3; 5; 5 Participants

Zosano Pharma Corporation Results May 2022 0.0% serious AE View details

Phase 3 N=391 Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Day 29 — -42.79; -59.92 Percent Change — p=0.0002

Pfizer Results May 2022 0.5% serious AE View details

Phase 3 N=105 Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

Infertility

Primary: Total Fertilization Proportion (i.e. Total Competent Proportion) — 0.59; 0.65 ratio

University of California, San Francisco Results Apr 2022 1.0% serious AE View details

Phase 3 N=15 Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

HIV-1-infection

Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml

Fundación FLS de Lucha Contra el Sida, las… Results Apr 2022 0.0% serious AE View details

Phase 3 N=364 Mirena Extension Trial

Contraception

Primary: Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use — 0.28 Pregnancies per 100 women years

Bayer Results Apr 2022 3.9% serious AE View details

Phase 3 N=3 A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia

Aplastic Anemia

Primary: Number of Participants With Hematologic Response at Week 12 — 2; 1 Participants

Pfizer Results Apr 2022 0.0% serious AE View details

Phase 3 N=114 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

Opioid-use Disorder · Hiv

Primary: Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed — 23; 21; 29; 29 Participants

Oregon Health and Science University Results Apr 2022 10.5% serious AE View details

Phase 3 N=338 Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Overweight · Obesity

Primary: Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) — -16.4; -6.4 Percentage of body weight — p=<0.0001

Novo Nordisk A/S Results Apr 2022 8.9% serious AE View details

Phase 3 N=225 Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes

Diabetes · Diabetes Mellitus, Type 1

Primary: Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery — 6.30; 6.26; 6.32; 6.26 Percentage glycosylated hemoglobin — p=<0.0001

Novo Nordisk A/S Results Apr 2022 36.9% serious AE View details

Phase 3 N=471 CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Uremic Pruritus

Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…

Cara Therapeutics, Inc. Results Apr 2022 27.5% serious AE View details

Phase 3 N=550 Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Non-Small Cell Lung Cancer

Primary: Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) — 12.1; 8.1 months — p=<0.0001

Ono Pharmaceutical Co., Ltd. Results Apr 2022 49.6% serious AE View details